 Suchitra Rao
Concepts (267)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Influenza, Human | 36 | 2025 | 622 | 10.630 |
Why?
| | Influenza Vaccines | 19 | 2025 | 539 | 4.870 |
Why?
| | Vaccination | 22 | 2025 | 1381 | 2.880 |
Why?
| | Respiratory Syncytial Virus Infections | 5 | 2025 | 128 | 2.570 |
Why?
| | Respiratory Tract Infections | 6 | 2025 | 390 | 2.450 |
Why?
| | Respiratory Syncytial Virus, Human | 4 | 2024 | 74 | 2.320 |
Why?
| | Hospitalization | 33 | 2025 | 2199 | 2.210 |
Why?
| | Systemic Inflammatory Response Syndrome | 6 | 2024 | 93 | 1.810 |
Why?
| | Influenza A Virus, H1N1 Subtype | 6 | 2025 | 148 | 1.620 |
Why?
| | Emergency Service, Hospital | 19 | 2025 | 2069 | 1.600 |
Why?
| | Child | 59 | 2025 | 21935 | 1.520 |
Why?
| | Child, Preschool | 41 | 2025 | 11074 | 1.420 |
Why?
| | Infant | 29 | 2025 | 9465 | 1.300 |
Why?
| | Antiviral Agents | 8 | 2025 | 744 | 1.190 |
Why?
| | Influenza A Virus, H3N2 Subtype | 6 | 2025 | 45 | 1.040 |
Why?
| | Retrospective Studies | 30 | 2025 | 15657 | 1.030 |
Why?
| | Coinfection | 2 | 2022 | 137 | 1.020 |
Why?
| | Absenteeism | 2 | 2024 | 49 | 1.020 |
Why?
| | Connective Tissue Diseases | 2 | 2023 | 84 | 0.990 |
Why?
| | Oseltamivir | 3 | 2025 | 12 | 0.970 |
Why?
| | Humans | 103 | 2025 | 137585 | 0.940 |
Why?
| | Polyomavirus Infections | 3 | 2016 | 31 | 0.940 |
Why?
| | Croup | 1 | 2024 | 19 | 0.900 |
Why?
| | Polyomavirus | 3 | 2016 | 12 | 0.890 |
Why?
| | Immunocompromised Host | 3 | 2021 | 202 | 0.880 |
Why?
| | Bronchiolitis | 1 | 2024 | 80 | 0.840 |
Why?
| | Colorado | 12 | 2023 | 4565 | 0.830 |
Why?
| | Ambulatory Care | 9 | 2025 | 546 | 0.810 |
Why?
| | Ageusia | 1 | 2022 | 1 | 0.810 |
Why?
| | Immunization Programs | 1 | 2025 | 213 | 0.800 |
Why?
| | Seizures | 3 | 2024 | 426 | 0.780 |
Why?
| | Metapneumovirus | 1 | 2022 | 16 | 0.780 |
Why?
| | Adolescent | 44 | 2025 | 21513 | 0.760 |
Why?
| | Intensive Care Units, Pediatric | 2 | 2021 | 233 | 0.720 |
Why?
| | Myocarditis | 1 | 2022 | 100 | 0.720 |
Why?
| | Viruses | 1 | 2022 | 113 | 0.700 |
Why?
| | Male | 52 | 2025 | 67762 | 0.690 |
Why?
| | Molecular Diagnostic Techniques | 1 | 2021 | 105 | 0.670 |
Why?
| | Endpoint Determination | 1 | 2020 | 77 | 0.660 |
Why?
| | Female | 52 | 2025 | 73304 | 0.650 |
Why?
| | Autoimmune Diseases | 1 | 2024 | 460 | 0.640 |
Why?
| | Seasons | 9 | 2025 | 547 | 0.620 |
Why?
| | Birth Order | 1 | 2019 | 14 | 0.610 |
Why?
| | Advisory Committees | 1 | 2020 | 219 | 0.610 |
Why?
| | Respiratory Tract Diseases | 2 | 2021 | 184 | 0.600 |
Why?
| | Streptococcal Infections | 1 | 2021 | 151 | 0.600 |
Why?
| | Onchocerciasis | 2 | 2015 | 7 | 0.600 |
Why?
| | Sinusitis | 1 | 2021 | 221 | 0.580 |
Why?
| | Encephalitis | 2 | 2017 | 136 | 0.580 |
Why?
| | United States | 32 | 2025 | 14841 | 0.530 |
Why?
| | Viral Load | 4 | 2024 | 466 | 0.530 |
Why?
| | Nervous System Diseases | 1 | 2020 | 266 | 0.530 |
Why?
| | Medical Audit | 1 | 2016 | 78 | 0.510 |
Why?
| | Anti-Bacterial Agents | 2 | 2024 | 1809 | 0.490 |
Why?
| | Host-Pathogen Interactions | 1 | 2019 | 364 | 0.490 |
Why?
| | Cohort Studies | 12 | 2025 | 5742 | 0.480 |
Why?
| | Family Characteristics | 3 | 2025 | 191 | 0.470 |
Why?
| | Enterovirus D, Human | 1 | 2016 | 85 | 0.460 |
Why?
| | Spinal Cord Diseases | 1 | 2015 | 42 | 0.460 |
Why?
| | Acyclovir | 1 | 2015 | 101 | 0.450 |
Why?
| | Attitude to Health | 1 | 2017 | 439 | 0.440 |
Why?
| | Case-Control Studies | 9 | 2023 | 3556 | 0.430 |
Why?
| | Ritonavir | 2 | 2024 | 74 | 0.420 |
Why?
| | Enterovirus Infections | 1 | 2016 | 177 | 0.420 |
Why?
| | Hospitals, Pediatric | 2 | 2025 | 508 | 0.420 |
Why?
| | Health Promotion | 1 | 2019 | 741 | 0.410 |
Why?
| | Young Adult | 19 | 2025 | 13209 | 0.400 |
Why?
| | Pandemics | 4 | 2025 | 1639 | 0.400 |
Why?
| | Infection Control | 1 | 2014 | 167 | 0.400 |
Why?
| | Infant, Newborn | 10 | 2025 | 6079 | 0.390 |
Why?
| | Mothers | 1 | 2019 | 754 | 0.390 |
Why?
| | Electronic Health Records | 5 | 2025 | 1069 | 0.380 |
Why?
| | Adult | 35 | 2025 | 37929 | 0.380 |
Why?
| | Outpatients | 3 | 2025 | 396 | 0.370 |
Why?
| | Gene Expression Profiling | 1 | 2019 | 1774 | 0.370 |
Why?
| | Virus Diseases | 1 | 2014 | 212 | 0.370 |
Why?
| | Practice Patterns, Physicians' | 3 | 2025 | 1313 | 0.370 |
Why?
| | Cross Infection | 1 | 2014 | 256 | 0.370 |
Why?
| | Anticonvulsants | 2 | 2024 | 217 | 0.360 |
Why?
| | Health Personnel | 1 | 2017 | 710 | 0.350 |
Why?
| | Hematologic Diseases | 1 | 2011 | 62 | 0.350 |
Why?
| | Liver Abscess, Amebic | 1 | 2009 | 3 | 0.310 |
Why?
| | Stomach Rupture | 1 | 2009 | 3 | 0.310 |
Why?
| | Pericardial Effusion | 1 | 2009 | 19 | 0.300 |
Why?
| | Parents | 1 | 2017 | 1347 | 0.300 |
Why?
| | Program Evaluation | 2 | 2025 | 898 | 0.290 |
Why?
| | Pleural Effusion | 1 | 2009 | 54 | 0.290 |
Why?
| | Peritonitis | 1 | 2009 | 84 | 0.290 |
Why?
| | Electroencephalography | 2 | 2024 | 423 | 0.290 |
Why?
| | Immunization, Secondary | 3 | 2022 | 87 | 0.280 |
Why?
| | Risk Factors | 9 | 2025 | 10388 | 0.270 |
Why?
| | Acute Kidney Injury | 1 | 2015 | 815 | 0.260 |
Why?
| | Severity of Illness Index | 5 | 2025 | 2828 | 0.260 |
Why?
| | Motivation | 2 | 2022 | 570 | 0.250 |
Why?
| | Angiostrongylus cantonensis | 2 | 2018 | 3 | 0.250 |
Why?
| | Strongylida Infections | 2 | 2018 | 7 | 0.250 |
Why?
| | Body Mass Index | 3 | 2024 | 2389 | 0.250 |
Why?
| | Prospective Studies | 6 | 2025 | 7604 | 0.250 |
Why?
| | Leukoencephalitis, Acute Hemorrhagic | 1 | 2025 | 4 | 0.240 |
Why?
| | Vaccines, Synthetic | 5 | 2022 | 126 | 0.230 |
Why?
| | Respiratory Syncytial Virus Vaccines | 1 | 2024 | 36 | 0.220 |
Why?
| | Virus Shedding | 1 | 2024 | 48 | 0.220 |
Why?
| | Disease Progression | 4 | 2024 | 2757 | 0.210 |
Why?
| | Pediatrics | 2 | 2025 | 1101 | 0.210 |
Why?
| | Aged | 16 | 2025 | 23961 | 0.210 |
Why?
| | Middle Aged | 20 | 2025 | 33479 | 0.210 |
Why?
| | Observational Studies as Topic | 1 | 2024 | 117 | 0.210 |
Why?
| | Antigens, Viral | 1 | 2024 | 178 | 0.210 |
Why?
| | Vaccines, Combined | 4 | 2023 | 48 | 0.200 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2016 | 346 | 0.200 |
Why?
| | RNA, Messenger | 7 | 2024 | 2833 | 0.200 |
Why?
| | Physicians | 2 | 2023 | 910 | 0.200 |
Why?
| | Child, Hospitalized | 1 | 2023 | 49 | 0.200 |
Why?
| | Propensity Score | 1 | 2024 | 294 | 0.190 |
Why?
| | Vital Signs | 1 | 2022 | 43 | 0.190 |
Why?
| | Inpatients | 2 | 2017 | 500 | 0.190 |
Why?
| | Length of Stay | 2 | 2025 | 1215 | 0.190 |
Why?
| | Viral Vaccines | 1 | 2023 | 98 | 0.190 |
Why?
| | Cough | 1 | 2022 | 122 | 0.180 |
Why?
| | Patient Readmission | 2 | 2024 | 697 | 0.180 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 9 | 0.180 |
Why?
| | Patient Acceptance of Health Care | 2 | 2024 | 806 | 0.180 |
Why?
| | Guideline Adherence | 1 | 2025 | 556 | 0.170 |
Why?
| | Drug Utilization | 2 | 2024 | 169 | 0.170 |
Why?
| | Public Health | 1 | 2025 | 588 | 0.160 |
Why?
| | Confusion | 1 | 2020 | 28 | 0.160 |
Why?
| | Encephalitis, Viral | 1 | 2020 | 43 | 0.160 |
Why?
| | Immunization Schedule | 2 | 2021 | 197 | 0.160 |
Why?
| | Critical Pathways | 1 | 2020 | 96 | 0.160 |
Why?
| | Antibodies, Viral | 2 | 2023 | 625 | 0.150 |
Why?
| | Brain Diseases | 1 | 2020 | 141 | 0.150 |
Why?
| | Aged, 80 and over | 7 | 2025 | 7635 | 0.150 |
Why?
| | Education, Medical, Continuing | 1 | 2019 | 127 | 0.150 |
Why?
| | Information Dissemination | 1 | 2020 | 218 | 0.150 |
Why?
| | Oxygen | 1 | 2023 | 931 | 0.140 |
Why?
| | Needs Assessment | 1 | 2020 | 376 | 0.140 |
Why?
| | Infant, Small for Gestational Age | 1 | 2019 | 92 | 0.140 |
Why?
| | Infant, Low Birth Weight | 1 | 2019 | 141 | 0.140 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2022 | 394 | 0.140 |
Why?
| | Interprofessional Relations | 1 | 2020 | 283 | 0.140 |
Why?
| | Reminder Systems | 1 | 2019 | 169 | 0.140 |
Why?
| | Adjuvants, Immunologic | 1 | 2019 | 226 | 0.140 |
Why?
| | Central Nervous System Diseases | 1 | 2018 | 69 | 0.140 |
Why?
| | Anti-Infective Agents | 1 | 2020 | 255 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2020 | 159 | 0.140 |
Why?
| | Pneumonia | 2 | 2016 | 639 | 0.140 |
Why?
| | Cost of Illness | 2 | 2016 | 308 | 0.130 |
Why?
| | Disease Outbreaks | 2 | 2020 | 395 | 0.130 |
Why?
| | Nurses | 1 | 2019 | 180 | 0.130 |
Why?
| | Adiposity | 1 | 2022 | 518 | 0.130 |
Why?
| | Tertiary Healthcare | 1 | 2016 | 33 | 0.130 |
Why?
| | Philippines | 1 | 2016 | 51 | 0.130 |
Why?
| | Epidemiologic Studies | 1 | 2016 | 72 | 0.130 |
Why?
| | Fatigue | 1 | 2018 | 329 | 0.130 |
Why?
| | Neoplasms | 1 | 2011 | 2671 | 0.120 |
Why?
| | Onchocerca | 1 | 2015 | 2 | 0.120 |
Why?
| | Nasal Cavity | 1 | 2016 | 52 | 0.120 |
Why?
| | Critical Care | 1 | 2021 | 601 | 0.120 |
Why?
| | Patient Discharge | 2 | 2019 | 897 | 0.120 |
Why?
| | Urban Population | 1 | 2019 | 479 | 0.120 |
Why?
| | Influenza B virus | 2 | 2025 | 44 | 0.120 |
Why?
| | Zoonoses | 1 | 2015 | 33 | 0.120 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 36 | 0.120 |
Why?
| | Catheterization, Peripheral | 1 | 2016 | 109 | 0.120 |
Why?
| | Mental Disorders | 1 | 2024 | 1077 | 0.120 |
Why?
| | Encephalitis, Varicella Zoster | 1 | 2015 | 17 | 0.120 |
Why?
| | Hospital Mortality | 3 | 2025 | 911 | 0.120 |
Why?
| | Encephalitis, Herpes Simplex | 1 | 2015 | 21 | 0.120 |
Why?
| | Dog Diseases | 1 | 2015 | 64 | 0.120 |
Why?
| | Rural Population | 1 | 2019 | 563 | 0.110 |
Why?
| | Time Factors | 4 | 2025 | 6828 | 0.110 |
Why?
| | Computational Biology | 1 | 2019 | 644 | 0.110 |
Why?
| | Incidence | 1 | 2021 | 2804 | 0.110 |
Why?
| | Infusions, Intravenous | 1 | 2015 | 413 | 0.110 |
Why?
| | Hospitals | 3 | 2024 | 691 | 0.110 |
Why?
| | Cervical Vertebrae | 1 | 2015 | 137 | 0.110 |
Why?
| | Pregnancy | 3 | 2022 | 6763 | 0.100 |
Why?
| | Transcriptome | 1 | 2019 | 971 | 0.100 |
Why?
| | Survival Rate | 1 | 2017 | 1972 | 0.090 |
Why?
| | Quality Improvement | 1 | 2020 | 1178 | 0.090 |
Why?
| | Meningitis | 1 | 2013 | 79 | 0.090 |
Why?
| | Logistic Models | 1 | 2016 | 2074 | 0.090 |
Why?
| | Decision Making | 1 | 2018 | 900 | 0.090 |
Why?
| | Laboratories | 2 | 2021 | 113 | 0.090 |
Why?
| | Registries | 1 | 2019 | 2035 | 0.090 |
Why?
| | Eosinophilia | 1 | 2013 | 218 | 0.080 |
Why?
| | Critical Illness | 1 | 2016 | 811 | 0.080 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2016 | 1477 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2025 | 5778 | 0.080 |
Why?
| | Internship and Residency | 1 | 2019 | 1147 | 0.080 |
Why?
| | Paromomycin | 1 | 2009 | 3 | 0.080 |
Why?
| | Trophozoites | 1 | 2009 | 4 | 0.080 |
Why?
| | Entamoeba histolytica | 1 | 2009 | 7 | 0.080 |
Why?
| | DNA, Viral | 1 | 2011 | 364 | 0.080 |
Why?
| | Metronidazole | 1 | 2009 | 20 | 0.080 |
Why?
| | Antiprotozoal Agents | 1 | 2009 | 16 | 0.080 |
Why?
| | Prevalence | 2 | 2025 | 2734 | 0.070 |
Why?
| | Drainage | 1 | 2009 | 173 | 0.070 |
Why?
| | Intensive Care Units | 2 | 2025 | 827 | 0.070 |
Why?
| | Human Experimentation | 1 | 2007 | 13 | 0.070 |
Why?
| | Insect Bites and Stings | 1 | 2007 | 12 | 0.070 |
Why?
| | Plasmodium falciparum | 1 | 2007 | 30 | 0.070 |
Why?
| | Malaria, Falciparum | 1 | 2007 | 27 | 0.070 |
Why?
| | Culicidae | 1 | 2007 | 37 | 0.070 |
Why?
| | Treatment Outcome | 2 | 2023 | 10811 | 0.070 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3715 | 0.060 |
Why?
| | Viral Proteins | 1 | 2009 | 342 | 0.060 |
Why?
| | Animals | 6 | 2018 | 36940 | 0.060 |
Why?
| | Longitudinal Studies | 2 | 2025 | 2844 | 0.060 |
Why?
| | Plasmapheresis | 1 | 2025 | 24 | 0.060 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 622 | 0.060 |
Why?
| | Contact Tracing | 1 | 2025 | 27 | 0.060 |
Why?
| | Basic Reproduction Number | 1 | 2025 | 5 | 0.060 |
Why?
| | Safety | 1 | 2007 | 338 | 0.060 |
Why?
| | Brain | 1 | 2017 | 2668 | 0.060 |
Why?
| | Magnetic Resonance Imaging | 1 | 2017 | 3566 | 0.060 |
Why?
| | Influenza A virus | 1 | 2025 | 107 | 0.060 |
Why?
| | Lopinavir | 1 | 2024 | 30 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2009 | 1483 | 0.060 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2025 | 128 | 0.060 |
Why?
| | Immunity, Herd | 1 | 2024 | 5 | 0.050 |
Why?
| | Early Diagnosis | 1 | 2025 | 242 | 0.050 |
Why?
| | Disability Evaluation | 1 | 2025 | 290 | 0.050 |
Why?
| | Genotype | 1 | 2009 | 1916 | 0.050 |
Why?
| | Pediatricians | 1 | 2025 | 129 | 0.050 |
Why?
| | Drug Combinations | 1 | 2024 | 343 | 0.050 |
Why?
| | Acetamides | 1 | 2023 | 36 | 0.050 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5472 | 0.050 |
Why?
| | Bradycardia | 1 | 2023 | 55 | 0.050 |
Why?
| | Comparative Effectiveness Research | 1 | 2024 | 152 | 0.050 |
Why?
| | Bayes Theorem | 1 | 2025 | 405 | 0.050 |
Why?
| | RNA, Messenger, Stored | 1 | 2022 | 7 | 0.050 |
Why?
| | Vaccination Coverage | 1 | 2023 | 82 | 0.050 |
Why?
| | Multiple Organ Failure | 1 | 2023 | 128 | 0.050 |
Why?
| | Patient Acuity | 1 | 2022 | 47 | 0.050 |
Why?
| | Diabetic Ketoacidosis | 1 | 2023 | 201 | 0.040 |
Why?
| | Obesity | 2 | 2024 | 2992 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1946 | 0.040 |
Why?
| | Hypoglycemia | 1 | 2023 | 445 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2009 | 2691 | 0.040 |
Why?
| | Machine Learning | 1 | 2023 | 493 | 0.040 |
Why?
| | Research Design | 1 | 2024 | 1139 | 0.030 |
Why?
| | Pediatric Obesity | 1 | 2024 | 601 | 0.030 |
Why?
| | Practice Guidelines as Topic | 1 | 2025 | 1587 | 0.030 |
Why?
| | Health Information Systems | 1 | 2016 | 17 | 0.030 |
Why?
| | Population Surveillance | 1 | 2020 | 482 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2021 | 1289 | 0.030 |
Why?
| | Administration, Intravenous | 1 | 2016 | 155 | 0.030 |
Why?
| | Follow-Up Studies | 1 | 2025 | 5131 | 0.030 |
Why?
| | Databases, Factual | 1 | 2022 | 1357 | 0.030 |
Why?
| | Comorbidity | 1 | 2021 | 1622 | 0.030 |
Why?
| | Southwestern United States | 1 | 2015 | 91 | 0.030 |
Why?
| | Treatment Failure | 1 | 2016 | 356 | 0.030 |
Why?
| | Cats | 1 | 2015 | 210 | 0.030 |
Why?
| | Risk Assessment | 1 | 2024 | 3457 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3196 | 0.030 |
Why?
| | Dogs | 1 | 2015 | 413 | 0.030 |
Why?
| | Administration, Oral | 1 | 2016 | 816 | 0.030 |
Why?
| | Age Factors | 1 | 2021 | 3295 | 0.030 |
Why?
| | DNA, Helminth | 1 | 2013 | 20 | 0.030 |
Why?
| | Algorithms | 1 | 2020 | 1704 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 1062 | 0.020 |
Why?
| | Cross Reactions | 1 | 2009 | 133 | 0.020 |
Why?
| | Seroepidemiologic Studies | 1 | 2009 | 165 | 0.020 |
Why?
| | Age Distribution | 1 | 2009 | 392 | 0.020 |
Why?
| | Parasitemia | 1 | 2007 | 13 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2009 | 852 | 0.020 |
Why?
|
|
Rao's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|